ProCE Banner Activity

SELECT-D: Dalteparin vs Rivaroxaban Anticoagulation Therapy for Patients With Cancer at Risk of VTE Recurrence

Slideset Download
Conference Coverage
Compared with dalteparin, rivaroxaban was associated with a lower incidence of VTE recurrence within 6 months but a higher incidence of clinically relevant bleeding events.

Released: December 13, 2017

Expiration: December 12, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Novartis Pharmaceuticals Corporation